Pressure points on pharmaceutical industry executives: what lies ahead?

被引:6
作者
Glass, Harold E. [1 ,2 ]
Poli, Laurence G. [3 ]
机构
[1] Univ Sci Philadelphia, Hlth Policy, Philadelphia, PA 19139 USA
[2] TTC LLC, Philadelphia, PA USA
[3] Ctr Performance Excellence, Div MME LLC, Philadelphia, PA USA
关键词
Pharmaceuticals industry; Drugs; Research and development;
D O I
10.1108/17506120910948520
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose - The pharmaceutical industry faces significant challenges in the immediate future, including drug safety, intellectual property in emerging markets, industry image, and the overall effect of marketing. To remain effective, pharmaceutical executives must translate these challenges to the industry into solutions, find relationships between individual issues, and group these issues into larger themes. The purpose of this paper is to study the issues that senior industry executives perceive the pharmaceutical industry faces and how they can organize these issues into high-impact "pressure points." Design/methodology/approach - Using a modified approach to the Delphi technique, 70 senior pharmaceutical industry executives rated issues facing the pharmaceutical industry. Their responses were then examined using factor analysis. Findings - The study concludes that concerns about the industry's future must be accompanied by a concerted effort to communicate and market the importance drugs play in improving and extending lives. Practical implications - These will influence political factors that effect new drug development. Originality/value - The study develops a list of potential major issues facing the industry over the next three to five years.
引用
收藏
页码:74 / 83
页数:10
相关论文
共 26 条
[1]   Newly approved does not always mean new and improved [J].
Anderson, Geoffrey M. ;
Juurlink, David ;
Detsky, Allan S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (13) :1598-1600
[2]  
[Anonymous], 2006, GAO0749
[3]  
Catlin A., 2008, HLTH SPENDING, V21, P14
[4]  
Chase J., 2008, MED MARKET MEDIA, V43, P6
[5]  
Dickinson J., 2007, MED MARKET MEDIA, V42, P14
[6]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[7]   The Cost of Biopharmaceutical R&D: Is Biotech Different? [J].
DiMasi, Joseph A. ;
Grabowski, Henry G. .
MANAGERIAL AND DECISION ECONOMICS, 2007, 28 (4-5) :469-479
[8]  
Duffield C, 1988, Aust J Adv Nurs, V6, P41
[9]   Evaluating the use of exploratory factor analysis in psychological research [J].
Fabrigar, LR ;
Wegener, DT ;
MacCallum, RC ;
Strahan, EJ .
PSYCHOLOGICAL METHODS, 1999, 4 (03) :272-299
[10]  
Jarvis LM, 2007, CHEM ENG NEWS, V85, P32